Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.

NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.

In this episode, we tackle:
-What network meta-analyses actually measure and how they're conducted
-Why two NMAs can reach opposite conclusions about drug effectiveness
-Red flags to watch for when evaluating NMA quality and reliability
-Practical guidance for incorporating NMA findings into clinical practice

Perfect for dermatology providers, researchers, and pharma professionals who want to critically evaluate the evidence behind treatment guidelines. Tune in for expert analysis that might surprise you about this increasingly common research methodology.

Listen now to become a smarter consumer of dermatology research!

And be sure to discover more at Scholars In Medicine!

Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers.

We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.

But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?

Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!

Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above. Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!
So join us for a deep dive into CSU, and yes, there will be trivia at the end!

Visit the ⁠Scholars In Medicine⁠ website for more.

Get ahead of the curve with Derms on Drugs as we break down the most exciting new dermatology research! This week features game-changing studies including an oral probiotic with stunning results for atopic dermatitis, JAK inhibitors for bullous pemphigoid, and IL-23 inhibitors tackling guttate psoriasis.

Plus, we dive deep into:

• Dermoscopy advances for managing longitudinal melanonychia

• If failing an IL-13 inhibitor affects the chances of doing well on another IL-13 inhibitor

• New data on IL-13 inhibitor induced conjunctivitis

• Red light PDT efficacy for superficial basal cell carcinoma

• Early systemic PDE4 inhibition strategies in psoriasis

• Follicular event insights from tapinarof studies

• PDE4 inhibition potential for vitiligo treatment

Perfect for dermatology providers who want cutting-edge clinical pearls they can apply immediately. Tune in for evidence-based insights, practical takeaways, and the signature Derms on Drugs commentary that keeps you engaged while staying current.

See more at ScholarsInMedicine.com

Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.

We cover:

• Can moisturizing infants prevent atopic dermatitis?
• New sunscreen ingredients headed for the US market
• Insights from lichenoid eruptions linked to immune checkpoint inhibitors
• What to do if oral JAKs fail in alopecia areata
• Does CeraVe outperform other moisturizers?
• The real risk of cardiovascular and thromboembolic events with JAK inhibitors
• Why IL-13 inhibitors differ in likelihood of causing arthralgias
• Advances in autologous skin cell transplantation for vitiligo
• The safety of patients self-injecting triamcinolone for acne
• New findings on hypersensitivity reactions after sentinel lymph node biopsy
• Can patch testing help with burning mouth syndrome?
• A drug that reduces cardiovascular mortality in hidradenitis suppurativa
• Novel approaches for chronic erythema nodosum, frontal fibrosing alopecia, and cheilitis granulomatosis
  

Join us for concise, actionable updates and real-world pearls you can apply in clinic today. Whether you’re managing complex cases or keeping up with the literature, this is one episode you don’t want to miss.
Listen now and stay ahead in dermatology!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling all kinds of medical diseases - whether we're talking about patients who can't access (or don't respond adequately) to our highly effective FDA approved drugs for psoriasis, atopic dermatitis, alopecia areata, hidradenitis or about patients with diseases that don't have an extremely effective FDA approved drug - things like lichen planus, granuloma annulare, dermatitis herpetiformis and many, many more. This week, we talk through dapsone, roflumilast, and acitretin.
In this episode, you’ll learn:

Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.
Tune in for clinical pearls and expert insights you can put to work in your practice!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling tough diseases like lichen planus, granuloma annulare, psoriasis, atopic dermatitis, and alopecia areata, especially when FDA-approved options fall short or are inaccessible. Join Derms on Drugs and guest expert Dr. Scott Drew as we share practical pearls for using methotrexate, mycophenolate, cyclosporine, dapsone, roflumilast, and more.
In this episode, you’ll learn:
--When and why to reach for these time-tested therapies in real-world practice
--How to monitor labs and counsel patients for safety and success
--Tips for discussing off-label treatments and navigating complex cases
Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.
Tune in for clinical pearls and expert insights you can put to work in your practice!
Article titles:
1. Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial
2. Lower Oncogenic Risk with Dermatologic Use of Mycophenolate Mofetil Compared to Transplant Prophylaxis: A Retrospective Study
3. Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

Today on Derms on Drugs we’ve got the fabulous Dr. Heather Woolery-Lloyd with us, and yes—we’re talking sunscreens. Don’t roll your eyes, because we’re going way past “SPF 30 or 50?” into the good stuff: how these lotions and potions actually work, which myths need to finally get buried, and why tinted sunscreens aren’t just makeup but legit medicine for skin of color.

We’ll also dish on the brand-new Aussie rules for UV protection and spill which brands actually look good on darker skin without turning you into a ghost.

And because no episode is complete without it, we’ll detour into lifestyle hacks, chat a little nutrition, and finish with our usual trivia shenanigans.

So, grab your SPF (tinted or not, we don’t judge), and let’s dive in"